Induced Parkinson’s Disease mouse models – MPTP Mouse Model of Parkinson’s Disease
Rapidly evaluate the neuroprotective and neuroinflammation-targeting effects of your novel therapeutic, leveraging the MPTP-induced Parkinson’s disease mouse model
MPTP Mouse Model of Parkinson’s Disease Characteristics
The MPTP mouse model is one of the most widely used toxin-induced mouse models for Parkinson’s disease research and preclinical efficacy testing.
Degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) is one of the central pathological hallmarks underlying motor symptoms in Parkinson’s disease. Injecting wild-type mice with MPTP, a neurotoxin that selectively targets dopaminergic neurons of the nigrostriatal pathway, results in key pathological and behavioral phenotypes relevant to Parkinson’s disease. Following systemic administration, MPTP readily crosses the blood-brain barrier where it is metabolized it into its active toxic metabolite, MPP+. MPP+ is then selectively taken up by dopamine transporters on dopaminergic neurons, where it induces mitochondrial complex I dysfunction, oxidative stress, neuroinflammation, and ultimately dopaminergic neurodegeneration, reproducing key disease mechanisms highly relevant to Parkinson’s disease pathology.
Compared with transgenic α-synuclein mouse models, the MPTP model offers a fast induction of Parkinson’s disease-like pathology with flexible study timelines. At InnoSer, the MPTP mouse model can be used as a rapid and translationally relevant research tool for performing early-stage efficacy testing of neuroprotective compounds, anti-inflammatory therapeutics, and NLRP3 inflammasome inhibitors.
✓ The MPTP mouse model represents a rapid mouse model of dopaminergic degeneration
✓ MPTP dosing leads to motor impairments relevant to Parkinson’s disease
✓ InnoSer’s in-house validation has demonstrated that MPTP dosing leads to neuroinflammatory activation, including NLRP3 inflammasome signalling
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. Our in-house neurology experts have long standing experience with modelling PD in vivo and are help guide your decision on choosing the best model fit for your current research goals.
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
C'est ici que commence votre recherche en neurologie.
Choisissez en toute confiance le modèle adapté à vos recherches
MPTP Mouse Model of Parkinson’s Disease Sample Data
The MPTP mouse model represents a rapid mouse model of Parkinson’s disease, suitable for early-stage efficacy and/or proof of concept studies targeting neuroinflammation.
MPTP administration leads to a decrease in spontaneous activity assessed using the PhenoTyperTM cages days following injection, which is partially prevented by co-administration of a neuroprotectant. The activity of mice was tracked in their automated home cages; mice display a variety of spontaneous behaviours tracked at high resolution with video cameras and do not require human intervention.
The MPTP mouse model represents a rapid mouse model of Parkinson’s disease, suitable for early-stage efficacy and/or proof of concept studies targeting neuroinflammation.
InnoSer’s in-house data has demonstrated that MPTP administration leads to NLRP3 inflammasome activation in the substantia nigra (SN) as detected by fluorescence immunohistochemistry (IHC).
MPTP Mouse Model of Parkinson’s Disease Readouts
Histopathology analyses
Test the efficacy of your treatments with the following markers:
- Neuroinflammation markers (i.e., Iba1, Asc)
Les personnes qui travaillent sur vos recherches
Thomas Vogels, docteur en sciences, In Vivo Neurologie Directeur d'étude
Dirige une équipe d'experts scientifiques possédant une vaste expérience de nos modèles de neurologie afin de vous aider à choisir le modèle le plus adapté et vous guide dans votre conception optimale conception d’étude. Nous vous proposons la solution pour accélérerele rythme le développement de vos médicaments.
Vous rencontrez des difficultés pour faire passer vos principes actifs à travers la barrière hémato-encéphalique?
Découvrez comment la perturbation de la barrière hémato-encéphalique (BHE) par ultrasons SonoCloud® peut améliorer l'absorption cérébrale, sans modifier votre composé.
Foire aux questions
How does the MPTP mouse model differ to other available Parkinson’s disease mouse models?
The MPTP model belongs to the toxin-induced class of Parkinson’s disease mouse models and differs substantially from transgenic and α-synuclein spreading models. Compared with transgenic α-synuclein models such as the M83 mouse model, the MPTP model provides rapid study timelines driven by acute neurotoxicity-driven pathology manifesting as dopaminergic neurodegeneration with associated neuroinflammatory components (i.e., NLRP3 inflammasome activation).
Compared with transgenic Parkinson’s disease mouse models, the MPTP model offers shorter study timelines, high reproducibility, and straightforward pharmacological intervention paradigms. However, unlike toxin-induced models, transgenic α-synuclein mouse models capture progressive proteinopathy-driven disease biology. InnoSer works with the M83 A53T α-synuclein transgenic mouse model, which overexpresses human mutant α-synuclein under the mouse prion promoter and develops progressive α-synuclein aggregation, Lewy body-like pathology, motor impairment, and neurodegeneration over time.
In contrast to toxin-induced Parkinson’s disease mouse models and transgenic alpha-synuclein mouse models, αlpha-synuclein PFF seeding mouse models focus on aggregation and propagation of pathological αlpha-synuclein species across connected brain regions. These α-synuclein seeding and spreading models are increasingly considered among the most translationally relevant preclinical Parkinson’s disease models for studying aggregation-targeting therapeutics, propagation inhibitors, and target engagement strategies. InnoSer works with the alpha-synuclein PFF seeding mouse model, which reproduces the prion-like propagation of pathological α-synuclein across synaptically connected brain regions. InnoSer also collaborates on advanced AAV α-synuclein overexpression and combined AAV + PFF paradigms, which may be relevant depending on your therapeutic strategy and target biology.
Because each Parkinson’s disease mouse model captures distinct aspects of disease biology, selecting the appropriate platform depends strongly on your therapeutic modality, target biology, mechanism of action, and desired translational endpoints.
Is the MPTP mouse model relevant for NLRP3 inflammasome research?
Yes, InnoSer’s in-house validation data has confirmed NLRP3 inflammasome activation in MPTP-treated mice alongside motor impairments, making the model directly relevant to neuroinflammation-targeting therapeutic strategies.
MPTP exerts its neurotoxicity through a cascade of oxidative stress, mitochondrial complex I inhibition, neuroinflammation, and excitotoxicity acting in concert to cause dopaminergic neuronal damage, and neuroinflammatory activation, including microglial NLRP3 inflammasome assembly. NLRP3 inhibitors, microglial modulators, and anti-neuroinflammatory biologics are therefore well-positioned for evaluation in InnoSer’s MPTP model.
Découvrez d'autres modèles de maladies pertinents
Découvrez les dernières recherches d'InnoSer
![Cognitive profiling in the APP[V717I]xTau[P301S] mouse model](https://www.innoserlaboratories.com/wp-content/uploads/2026/07/Figure-1-MWM.png)
Cognitive profiling in the APP[V717I]xTau[P301S] mouse model
In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...
![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]
Dans la lettre d'information de ce mois-ci, nous mettons en avant et approfondissons nos connaissances acquises grâce à l'utilisation du modèle murin Tau[P301S] (décrit à l'origine par Allen et al., 2002), ainsi que son applicabilité dans la recherche préclinique. Les femelles et les mâles...
Panels de biomarqueurs cliniquement pertinents pour des études d'efficacité exhaustives sur des modèles murins de la maladie d'Alzheimer
Les modèles murins validés d'InnoSer pour la maladie d'Alzheimer (MA) intègrent des panels de biomarqueurs pertinents sur le plan translationnel — couvrant les espèces de bêta-amyloïde (Aβ), les isoformes phosphorylées de la protéine Tau, ainsi que le marqueur précoce et sensible de la neurodégénérescence que constituent les neurofilaments légers...
![Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept
La souris Tau[P301S] reste l'un des modèles in vivo les plus reconnus pour l'évaluation de traitements ciblant les tauopathies, notamment la maladie d'Alzheimer et la démence frontotemporale (DFT). Présentée lors du congrès AD/PD 2025 à Vienne, cette affiche offre un aperçu complet...
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Les sites d'InnoSer aux Pays-Bas et en Belgique sont accrédités par l'AAALAC depuis 2016 et 2020, respectivement. Pour en savoir plus sur le programme d'accréditation de l'AAALAC, cliquez ici.
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides